In a comparative evaluation of biomarker potential using AUC, NMUR1 (AUC = 0.626) outperformed PD-L1 (AUC = 0.555), underscoring its viability as a biomarker in CRC immunotherapy (Figure S10C–I). This evidence concerns the gene CD274 and colorectal carcinoma.